Q2 2025 · 13F-HR
Catalio Capital Management, LPholdings as filed
Filed 2025-08-14 · accession 0001958125-25-000007
$476.9M
Reported value
40
Positions
2025-06-30
Period end
The Brief · Catalio Capital Management, LP · Q2 2025
AI · grounded in 13F
Catalio Capital Management, LP established a new position in Eli Lilly & Co LLY valued at $42.0M. The fund also initiated new stakes in BridgeBio Pharma Inc BBIO for $40.1M and Soleno Therapeutics Inc SLNO for $34.3M. Additional new positions include Ascendis Pharma A/S ASNDUSD, Intuitive Surgical Inc ISRG, and Edwards Lifesciences Corp EW.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 532457108 | LLY | ELI LILLY & CO | $42.0M | 8.81% | 53,916 | Common | SOLE |
| 10806X102 | BBIO | BRIDGEBIO PHARMA INC | $40.1M | 8.40% | 927,711 | Common | SOLE |
| 834203309 | SLNO | SOLENO THERAPEUTICS INC | $34.3M | 7.20% | 409,944 | Common | SOLE |
| 04351P101 | ASNDUSD | ASCENDIS PHARMA A/S | $31.1M | 6.51% | 179,926 | Common | SOLE |
| 46120E602 | ISRG | INTUITIVE SURGICAL INC | $30.8M | 6.46% | 56,674 | Common | SOLE |
| 28176E108 | EW | EDWARDS LIFESCIENCES CORP | $30.6M | 6.41% | 390,932 | Common | SOLE |
| 375558103 | GILD | GILEAD SCIENCES INC | $25.2M | 5.27% | 226,875 | Common | SOLE |
| 101137107 | BSX | BOSTON SCIENTIFIC CORP | $24.6M | 5.16% | 229,046 | Common | SOLE |
| 23282W605 | CYTK | CYTOKINETICS INC | $19.9M | 4.17% | 601,439 | Common | SOLE |
| 87164F105 | SNDX | SYNDAX PHARMACEUTICALS INC | $19.7M | 4.13% | 2,104,512 | Common | SOLE |
| 881624209 | TEVA | TEVA PHARMACEUTICAL INDS LTD | $19.6M | 4.11% | 1,170,372 | Common | SOLE |
| 218352102 | CORT | CORCEPT THERAPEUTICS INC | $17.6M | 3.68% | 239,125 | Common | SOLE |
| 632307104 | NTRA | NATERA INC | $16.4M | 3.45% | 97,297 | Common | SOLE |
| 00650F109 | ADPT | ADAPTIVE BIOTECHNOLOGIES COR | $16.3M | 3.41% | 1,396,445 | Common | SOLE |
| 252828108 | DNTH | DIANTHUS THERAPEUTICS INC | $13.9M | 2.92% | 746,527 | Common | SOLE |
| 86366E106 | GPCR | STRUCTURE THERAPEUTICS INC | $13.9M | 2.92% | 670,575 | Common | SOLE |
| 000899104 | ADMA | ADMA BIOLOGICS INC | $10.4M | 2.18% | 569,704 | Common | SOLE |
| 40637H109 | HALO | HALOZYME THERAPEUTICS INC | $10.0M | 2.09% | 191,529 | Common | SOLE |
| 90400D108 | RARE | ULTRAGENYX PHARMACEUTICAL IN | $7.8M | 1.63% | 213,402 | Common | SOLE |
| 61559X104 | MLTX | MOONLAKE IMMUNOTHERAPEUTICS | $7.7M | 1.61% | 162,596 | Common | SOLE |
| 71722W107 | PHAT | PHATHOM PHARMACEUTICALS INC | $6.4M | 1.35% | 672,290 | Common | SOLE |
| N90064101 | QURE | UNIQURE NV | $5.8M | 1.22% | 417,443 | Common | SOLE |
| 81663L200 | WGS | GENEDX HOLDINGS CORP | $5.7M | 1.19% | 61,507 | Common | SOLE |
| 74365U107 | TARA | PROTARA THERAPEUTICS INC | $4.9M | 1.03% | 1,626,370 | Common | SOLE |
| 690145206 | OM | OUTSET MED INC | $3.2M | 0.67% | 166,666 | Common | SOLE |
| 81734D104 | SEPN | SEPTERNA INC | $3.1M | 0.65% | 294,360 | Common | SOLE |
| 76029N106 | REPL | REPLIMUNE GROUP INC | $3.1M | 0.64% | 330,337 | Common | SOLE |
| 98937L105 | ZBIO | ZENAS BIOPHARMA INC | $2.1M | 0.44% | 215,314 | Common | SOLE |
| 92764N102 | VIR | VIR BIOTECHNOLOGY INC | $2.0M | 0.41% | 388,303 | Common | SOLE |
| 501976104 | KYTX | KYVERNA THERAPEUTICS INC | $1.8M | 0.38% | 586,909 | Common | SOLE |
| 254604101 | IRON | DISC MEDICINE INC | $1.6M | 0.34% | 30,661 | Common | SOLE |
| 359616109 | FULC | FULCRUM THERAPEUTICS INC | $1.3M | 0.27% | 188,304 | Common | SOLE |
| 055477103 | BCAX | BICARA THERAPEUTICS INC | $908,562 | 0.19% | 97,800 | Common | SOLE |
| 59102M104 | MGX | METAGENOMI INC | $782,910 | 0.16% | 528,993 | Common | SOLE |
| 48576U205 | KPTI | KARYOPHARM THERAPEUTICS INC | $629,316 | 0.13% | 146,013 | Common | SOLE |
| 44916K106 | HYPR | HYPERFINE INC | $546,921 | 0.11% | 760,035 | Common | SOLE |
| 59045L106 | — | MERSANA THERAPEUTICS INC | $463,954 | 0.10% | 1,567,413 | Common | SOLE |
| N0731H103 | ATAI | ATAI LIFE SCIENCES NV | $431,119 | 0.09% | 196,858 | Common | SOLE |
| 35168W103 | GUTS | FRACTYL HEALTH INC | $347,062 | 0.07% | 214,236 | Common | SOLE |
| 81728A207 | SNSE | SENSEI BIOTHERAPEUTICS INC | $126,280 | 0.03% | 14,718 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.